中国科学院武汉病毒所在抗肠道病毒EV71的新药物研究中取得进展

  • 武汉病毒研究所,EV71,新型药物NITD008,EV71病毒,核苷类似物
  • 武汉病毒研究所

肠道疾病对人类健康造成严重威胁。自肠道病毒71型(Enterovirus 71)首次确认以来,已在全球多个国家大规模爆发流行,而目前仍然没有有效的针对EV71病毒感染的疫苗或治疗方法。

最近,中国科学院武汉病毒研究所张波研究员课题组发现了能有效抑制EV71病毒的新型药物NITD008,并揭示了该药物的作用机制。NITD008作为核苷类似物,最先被报道为抗黄病毒的药物,该课题组通过细胞和动物实验发现该药物表现出良好的抗EV71病毒的能力。随后在药物联合实验中,联合疗法表现出更加显著有效的抗病毒能力。通过筛选耐药株、关键位点定点突变、蛋白质结构分析等,发现不同耐药株在3D蛋白质基因上出现相同的适应性突变(V63A3D),推测NITD008的作用靶点主要在3D蛋白上。同时发现3A可能通过与3D的相互作用而补偿其在病毒复制过程中丧失的部分功能。

该研究发现了抗EV71病毒的新型药物NITD008,并揭示了该药物对EV71的作用机制,提出联合疗法的重要性与可行性思路。研究成果发表于Journal of Virology 。

  该研究得到了国家重点基础研究发展计划(“973”计划)、国家自然科学基金等项目的资助。


This link:http://www.chemcd.com/news/2333.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.